On March 25, 2019, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (hereinafter referred to as the “Fosun Pharma”, stock code：600196.SH，02196.HK), the China's leading healthcare group released the 2018 Annual Corporate Social Responsibility Report together with the annual report. It is the 11th consecutive year to publish its CSR report.
Fosun Pharma CSR report focuses on a complete review of issues include strategy and governance, R&D, products and service quality, environmental protection, occupational health and safety, employee development and public welfare, to disclose information to help shareholders, clients, consumers, employees, partners and other stakeholders to learn of Fosun Pharma’s practice and achievements in CSR work in 2018.
“Innovation is the significant responsibility for the sustainable development of pharmaceutical enterprise”, stated Mr. Qiyu Chen, Chairman of Fosun Pharma. “Fosun Pharma pursues global leadership and hopes to continuously bring value to its shareholders. Every year, we’re dedicated to delivering out our annual financial report and CSR report as well.”
Since its establishment, Fosun Pharma has incorporated social responsibility into the company's sustainable development strategy, and actively fulfilled its corporate social responsibility to give back to the society. In March 2009, Fosun Pharma released its CSR report for the first time, and later it was subsequently prized No.1 in the Rankins CSR Ratings (RKS) in pharmaceutical industry every year. In 2018, due to its CSR outstanding performance, Fosun Pharma successively won honors including Golden Bee - Social Responsibility Report Evergreen Award, Outstanding Enterprises Award (The Listed Companies Association of Shanghai, etc.), and was selected into “ESG 50 Index” and Responsibility Cloud ESG100 Index.
In the field of social responsibility, Fosun Pharma has actively benchmarked the global industry leading enterprises and international Standards. In line with the core plan of sustainable development report (GRI Standards) from GRI (Global Reporting Initiative), the company’s 2018 CSR Report has met the requirements of “ESG Reporting Guide” from the Appendix 27 of Rules Governing the Listing of Securities on the Stock Exchange of Hong Kong Limited released by the the Stock Exchange of Hong Kong, and has referred to the national standard (GB/T36000) of social responsibility series. The company also entrusts SGS to provide independent verification service for the report. In addition to Fosun Pharma HQ, the verification also covers the on-site examination of its subsidiaries including Ahon Pharma and Hongqi Pharma, which embodies the openness and transparency of the report. As a veteran in the social responsibility industry for nearly 20 years, Mr. Zhihong Yu, the Director and Editor-in-Chief of China WTO Tribune said: “2018 Fosun Pharma CSR report is of high quality in China, and is increasingly worth expecting. The report provides a comprehensive review of the company for all stakeholders.” He continued: “This CSR report is outstanding in multiple dimensions including: the compliance of application standards, material topics the richness of content, the depth of data, etc., that reflect Fosun Pharma’s sophisticated CSR awareness and strong management capability.”